TOLERABILITY/PHARMACOKINETICS OF DAB389 IL 2 IN PATIENTS WITH SEVERE PSORIASIS

这是一项开放标签、剂量递增的多中心试验，以确定 3种剂量阿司匹林的安全性、耐受性和药代动力学参数 DAB389IL-2在重症银屑病患者中的表达剂量是选定的 因为之前的研究已经证明，不良体验 在较高剂量下发生的频率更高，并且疗效一直存在于 所有剂量。该方案探索了一种更低、更多样化的治疗方法。 时间表。还将对疗效进行评估。 总共45名患者将被分配到递增的剂量 3个剂量组(0.5、1.5和5.0ug/kg/d)中的一个。药效 每隔一周服用3天，共8周。

This is an open-label, dose-escalating multi-center trial to determine the safety, tolerability, and pharmacokinetic parameter of 3 doses of DAB389IL-2 in patients with severe psoriasis. The doses were chosen because previous studies have demonstrated that adverse experiences occur more frequently at higher doses and efficacy has been present at all doses. This protocol explores a lower and varied treatment schedule. Efficacy will also be assessed. A total of forty-five patients will be assigned in a dose escalating manner to one of the 3 dose groups (0.5, 1.5, and 5.0 ug/kg/day). Drug is administered 3 days every other week for 8 weeks.